Securities code: Yunnan Baiyao Group Co.Ltd(000538) securities abbreviation: Yunnan Baiyao Group Co.Ltd(000538) Announcement No.: 202219
Yunnan Baiyao Group Co.Ltd(000538) 2021 annual report summary
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. Tips of non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period reviewed by the board of directors √ applicable □ not applicable whether to convert accumulation fund into share capital □ yes √ no the company’s profit distribution plan of common stock reviewed and approved by the board of directors is: Based on the total share capital on the equity registration date when the distribution plan is implemented in the future
A cash dividend of 16.00 yuan (tax included) will be distributed to all shareholders for every 10 shares, and 4 bonus shares (tax included) will be given to all shareholders. The capital stock will not be converted from the accumulation fund.
Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Yunnan Baiyao Group Co.Ltd(000538) Stock Code: Yunnan Baiyao Group Co.Ltd(000538)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Qian Yinghui, Zhao Yan, Zhu Ruiying
Office address: No. 3686 Yunnan Baiyao Group Co.Ltd(000538) street, Chenggong District, Kunming City, Yunnan Province No. 3686 Yunnan Baiyao Group Co.Ltd(000538) street, Chenggong District, Kunming City, Yunnan Province
Fax: 087166303531087166203531
Tel: 087166226106087166226106
E-mail Yunnan Baiyao Group Co.Ltd(000538) [email protected]. [email protected]. 、 [email protected].
2. Introduction to main business or products during the reporting period
In 2021, the pharmaceutical industry policy, innovation and capital will be superimposed and the industrial ecosystem will be reconstructed. In the short term, the payment side and the medical insurance system are becoming more and more sophisticated and mature; On the supply side, the review of new drugs was accelerated, and the number of approved drugs increased. In the long run, the national healthy consumption demand will continue to drive the penetration rate of China Meheco Group Co.Ltd(600056) industry and jointly promote the deep transformation of the industrial chain to high-end. The company adheres to the long-term principle and complies with medical innovation, digital transformation and
The general trend of sustainable development, in-depth accumulation of brand potential energy, steady promotion of strategic layout, multi-channel construction of incentive mechanism, overall optimization of digital ability, comprehensive improvement of ESG performance, based on competitive advantage, starting from new possibilities, based on the field of expertise, starting from the field of user needs, making steady progress, and then promising.
Throughout the year, the company achieved an operating revenue of 36.374 billion yuan, a net increase of 3.631 billion yuan or 11.09% over 32.743 billion yuan in the same period of last year; The total profit was 3.482 billion yuan, down 3.319 billion yuan or 48.80% from 6.801 billion yuan in the same period last year; The net profit attributable to shareholders of listed companies was 2.804 billion yuan, down 2.712 billion yuan or 49.17% from 5.516 billion yuan in the same period last year; Profits and taxes reached 5.294 billion yuan, down 34.66% from 8.102 billion yuan in the same period last year; The weighted average return on net assets is 7.58%; The net profit excluding non recurring profit and loss was 3.339 billion yuan, an increase of 440 million yuan or 15.17% over 2.899 billion yuan in the same period of last year; The net cash flow from the company’s operating activities in the current period was 5.223 billion yuan, an increase of 1.394 billion yuan or 36.42% compared with 3.829 billion yuan in the same period of last year.
The company’s main business continues to maintain stable and healthy growth, and its new business is gradually arranged layer by layer around the company’s short, medium and long-term strategic points, so as to consolidate the company’s development potential.
(I) review of main work of the whole year
(1) Highlight the highlights of the main basic sector and constantly consolidate the existing advantages
1) The pharmaceutical business department adheres to the development concept of “linking specialties and users with services”, takes the pharmaceutical operation center as the core, and takes the device operation center and new channel operation center as the two wings. Through sector synergy, we can form distinctive competitive advantages and industry influence.
The pharmaceutical operation center has established professional academic IP (value content) projects and competitive IP projects to continuously empower Yunnan Baiyao Group Co.Ltd(000538) series products, classic general medicine series products and Panax notoginseng family products. Through deep market exploration, global marketing and all-round efforts, it has won public praise and market. The device operation center selects two sub areas of chronic disease pain and eye health, focuses on the ecological chain of “specialty, product and service” for positioning and promotion, and outputs functional, intelligent and digital family wearable devices, traditional Chinese medicine diagnosis and treatment equipment and other medical products. The new channel operation center grasps the opportunities of new tracks such as pharmaceutical e-commerce, Internet medicine and short video platform, shapes new scenes, educates new people, and creates a brand unique internet marketing IP and rapid growth model.
2) The health products division focuses on the new consumption field of functional personal care products. While maintaining the advantages of oral care product group, it expands the population of scalp care and skin beauty products, and promotes the transformation of product form from functional products to personalized and digital intelligent comprehensive personal care solutions. During the reporting period, the company made full use of the existing brand and resource advantages to comprehensively expand the product group and form a three-dimensional product matrix: the oral care product group expanded from a single Baiyao hemostatic toothpaste to customized toothpaste for different groups, as well as mouthwash, tooth flushing device and other categories of oral care products. Among them, the toothpaste category still gained more than 23% market share in 2021 when the growth rate of the industry slowed down, Maintain the first position of market share in the industry; The scalp care product group includes yangyuanqing brand shampoo, hair lotion and other products. With the scientific concept of oil control and anti stripping, it can quickly occupy the minds of the younger generation of consumers, increase consumer experience offline and explore a variety of operation modes through online integration and layout; The beauty skin product group has developed its mask, daily skin care products, and private customized skin care products.
At the same time, caizhiji online app (application) was officially launched in 2021. Through the touch of app, it can output personalized customized skin problem solutions and care solutions, continuously strengthen brand penetration, focus on people with personalized demands for skin management, and let customers experience caizhiji’s “skin science level” AI (artificial Intelligence) skin detection, care and other private experience services.
3) Guided by the needs of customers, the traditional Chinese medicine resources division focuses on the mining, cultivation, development and utilization of regional traditional Chinese medicine industry resources, and creates a continuously leading traditional Chinese medicine resources industry platform through digitization, specialization and branding, so as to provide users with systematic solutions and create long-term value.
The group has built a strategic third floor and guaranteed the supply of raw materials for marijuana industry. Based on the large varieties of genuine natural medicinal resources in Yunnan, cultivate a resource system with sustainable development and technical content, build a group of branded natural medicinal resources, and build a closed-loop ecosystem tracing the whole process from planting to recycling.
4) Yunnan Pharmaceutical Co., Ltd. (hereinafter referred to as the “provincial pharmaceutical company”) gives full play to the advantages of fine management and professional services. Facing the changes of the current industry situation and the tightening of the policy environment of medical reform, it redesigns the marketing operation system from various dimensions such as strategy and business model, and continues to lead the region in the wave of industry integration.
By striving for the main distribution channel, the provincial pharmaceutical company ensures the steady growth of sales, seizes the opportunity of hospital development and variety introduction, expands the distribution share and obtains the increment to the greatest extent. Strengthen the management of accounts receivable, realize refinement and specialization through data analysis and optimization, and improve the collection quality; Seize the opportunity of the national collection policy and pay close attention to the collection and cost management; According to the different characteristics of customers, implement one hospital and one policy. Strengthen channel construction, give full play to the network advantages of subsidiaries in the grass-roots medical market, and promote the coverage of cooperative manufacturers at the grass-roots level. Coordinate and assist each subsidiary company in the market development of third-party end customers such as single pharmacies and clinics in the region, and improve the omni-channel customer structure of non-medical institutions. Pay close attention to the policy dividend of “two channels”, improve the specialization level of pharmacies, do a good job in product introduction, continue to deepen PBM (drug welfare management) and chronic disease management, and provide whole process services around the patient’s medical path. Expand new categories and new markets, introduce household medical devices, and make up for the sales pressure caused by volume procurement by entering the hospital for epidemic prevention materials, striving for new product distribution, winning the bid and transferring distribution of inspection reagent projects and some high-value consumables projects.
5) In terms of tea business, Yunnan Baiyao Group Co.Ltd(000538) Tianyi tea products Co., Ltd. (hereinafter referred to as “Tianyi tea products”) has deeply cultivated the market, optimized the commercial layout and benign expansion of the market. In 2021, a number of new franchise stores were established to cultivate strategic customers, continuously optimize partners and implement the elimination mechanism. At present, the main brand Zui Chunqiu dealers have covered 25 provinces and cities in China. Zui Chunqiu dealers have gradually developed into a market model combining traditional market and professional circles from traditional professional market players to well-known enterprises in various cities.
Stabilize key customer groups and explore private customers. After years of operation, the key account team has accumulated important end customer resources and become a high-quality customer pool of Tianyi tea products. At the same time, it has laid a good customer foundation for establishing a high-quality private domain and accumulated rich customer maintenance experience.
(2) Cross regional strategic layout has accumulated a lot and formed a joint force through linkage and cooperation
1) Shanghai Pharmaceutical Group Co., Ltd. (hereinafter referred to as “Shanghai International Development Center”). In January 2021, Gubei office area of Yunnan Baiyao Group Co.Ltd(000538) Group Shanghai Co., Ltd. was officially opened, and the R & D, investment and operation organization established by the company based on Shanghai has begun to operate. In the second half of 2021, the Shanghai International Center project with a total investment of about 1.55 billion yuan was fully started. After completion, it will undertake the functions of Yunnan Baiyao Group Co.Ltd(000538) international operation center, R & D center and so on. By creating an integrated platform in Shanghai, laying out innovative R & D system, cultivating emerging business sectors, establishing a multidisciplinary R & D center, quickly introducing world-class talents and project resources around the world, gathering and allocating global resources, and promoting the process of science and technology and internationalization of the company.
At the same time, during the reporting period, the company reached equity cooperation and strategic cooperation between the two sides by participating in the subscription of Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as ” Shanghai Pharmaceuticals Holding Co.Ltd(601607) “) non-public issuance of A-shares. By virtue of Shanghai Pharmaceuticals Holding Co.Ltd(601607) high-quality platform and industrial resource coordination, the company further expanded Yunnan Baiyao Group Co.Ltd(000538) existing resource advantages, grasped the important opportunities of industrial integration, expanded the scale of main business, the layout of existing industries and improved the overall operation efficiency, Through the integration and coordination of regional complementarity and logistics warehousing, purchase and price negotiation, variety agency, brand promotion and new drug development, it is conducive to expand the scale of main business, improve operation efficiency and enhance the core competitiveness and profitability of enterprises.
2) Peking University – Yunnan Baiyao Group Co.Ltd(000538) Xi’An International Medical Investment Company Limited(000516) Research Center, as a platform for the company to explore the school enterprise cooperative R & D innovation mode, has successfully completed the construction of strategic R & D organization system. In May 2021, the first meeting (expansion meeting) of the first Council of Peking University – Yunnan Baiyao Group Co.Ltd(000538) Xi’An International Medical Investment Company Limited(000516) Research Center was successfully held in the Department of medicine of Peking University. At the meeting, the establishment of rules and regulations of the center was completed and the research center was officially unveiled. In the second half of the year, the software and hardware construction of the project and the decoration of scientific research sites were gradually promoted. At the same time, the academic exchange function of the medical research center was brought into full play, and many large-scale academic forums in China were successfully held. Based on the development orientation of the National Regional Medical Center, the center carries out project cooperation around the strategic track determined by the company, carries out cooperation in five fields: Oncology, trauma orthopedics, pharmacy, stomatology and medical beauty, gives full play to and shares the market advantages, talent advantages and technical advantages of both sides, realizes achievement transformation, cross integration and innovative development, and gradually gives full play to the R & D function of its medical research center.
3) Yunnan Baiyao Group Co.Ltd(000538) group (Hainan) Co., Ltd. (hereinafter referred to as “Hainan International Center”) is an ideal window for the company to efficiently integrate high-quality resources globally, effectively bridge the company’s industrial layout outside China, and build an international operation platform through the development of international trade, financial business and industrial marijuana business. In 2021, Hainan International Center successfully completed the registration and equity transfer of Yunfan private equity fund company, Yunfeng import and export trading company, Hainan import and export trading company, Yunnan Yunyao company and yunbaiyao Hong Kong Co., Ltd. (hereinafter referred to as “yunbaiyao Hong Kong”), gradually straightened out the management and business relations, basically completed the construction of the core team, and landed the business office space in Yunnan and Hainan, Basic systems such as industry, finance and tax control have been established, and the new and old businesses of all subsidiaries have been carried out smoothly and orderly as planned. At the same time, the whole marijuana industry chain is planned to be initially set up, and the import and export business is carried out in Yunnan and Hainan, which has taken a solid first step for the smooth development of Yunnan Baiyao Group Co.Ltd(000538) international business.
4) As the connecting point between China and foreign countries, Hong Kong is an ideal platform for Chinese enterprises to go global.
During the reporting period, the company has launched a comprehensive tender offer to acquire Bandung Holdings Group Co., Ltd. (hereinafter referred to as Bandung Holdings) through the establishment of yunbaiyao Hong Kong Co., Ltd. By holding Bandung holdings, an enterprise listed on the main board of the Hong Kong stock exchange, first, it is conducive to make full use of Hong Kong’s geographical advantages and convenient investment and financing conditions to serve the company’s globalization strategy, and carry out global industrial resource integration and talent team building with Bandung holdings as a platform; Second, it is conducive to further strengthen the integration of domestic and foreign industrial resources of Yunnan Baiyao Group Co.Ltd(000538) and build an overseas oriented industrial marijuana industry platform; Third, it is conducive to the introduction of health products and functional foods based on the characteristics of overseas resources, and the coordinated development with Yunnan Baiyao Group Co.Ltd(000538) existing health products business, so as to create a new ecology and seize the fast-growing health products and functional food market; Fourth, take advantage of Hong Kong’s fully open free trade market position and tax incentives to build international trade business of health-related products and raw materials.
(3) Build a talent team, gather knowledge and wisdom, scientifically encourage and share growth
1) Human capital has always been the key to driving the development of Baiyao
